OS Therapies Incorporated (OSTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OS Therapies Incorporated (OSTX) trades at $1.57 with AI Score 33/100 (Grade D). OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. Market cap: $69.92M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026OSTX stock analysis for 2026: Analysts have set a consensus price target of $11.49 for OS Therapies Incorporated, suggesting 631.7% upside from the current price of $1.57. The AI MoonshotScore is 33/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
OSTX: 1/1 perspectives are bearish.
How is this calculated? →OS Therapies Incorporated (OSTX) Healthcare & Pipeline Overview
OS Therapies Incorporated is a clinical-stage biopharmaceutical company specializing in treatments for osteosarcoma and other solid tumors. With a focus on innovative immunotherapies and antibody-drug conjugate technologies like OST-HER2 and OST-tADC, the company aims to address unmet needs in oncology within the biotechnology sector.
What Is the Investment Thesis for OSTX?
OS Therapies Incorporated presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on osteosarcoma and other solid tumors addresses a critical unmet need in oncology. Key value drivers include the clinical progress of OST-HER2 and OST-tADC, with successful clinical trial outcomes representing significant catalysts. The OST-tADC platform's tunable nature offers potential for broader applications across different cancer types. However, the company's small market capitalization of $69.92M and limited resources introduce substantial execution risk. Investors should closely monitor clinical trial data, regulatory milestones, and the company's ability to secure additional funding to support its development programs. The negative beta of -2.99 suggests the stock moves inversely to the market, which could be a consideration during market downturns.
Based on FMP financials and quantitative analysis
OSTX Key Highlights
- Focus on osteosarcoma and other solid tumors, addressing a critical unmet need in oncology.
- Pipeline includes OST-HER2, an off-the-shelf immunotherapy, and OST-tADC, an antibody-drug conjugate technology.
- OST-tADC platform features tunable pH-sensitive silicone linkers, offering a plug-and-play approach to drug conjugation.
- Incorporated in 2018, indicating a relatively young company in the biotechnology space.
- Based in Rockville, Maryland, a hub for biotechnology and pharmaceutical companies.
Who Are OSTX's Competitors?
OSTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| ARRY Array Technologies, Inc. | $6.94 | -0.37% | $1.07B | — |
| CRVS Corvus Pharmaceuticals, Inc. | $15.17 | -0.39% | $1.28B | 65 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OSTX's Key Strengths?
- Innovative technology platform (OST-tADC)
- Focus on a niche market with unmet needs (osteosarcoma)
- Pipeline of targeted therapies
- Experienced management team
What Are OSTX's Weaknesses?
- Limited financial resources
- Small market capitalization
- Early-stage clinical development
- Dependence on key personnel
What Could Drive OSTX Stock Higher?
- Initiation of Phase 1 clinical trial for OST-HER2 in Q3 2026.
- Preclinical data release for OST-tADC platform in Q4 2026.
- Continued enrollment in ongoing clinical studies.
- Potential for orphan drug designation for OST-HER2.
- Progress in securing strategic partnerships for co-development.
What Are the Key Risks for OSTX?
- Financial-distress signal — its Altman Z-Score of -30.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for OST-HER2 or OST-tADC.
- Regulatory delays or rejection of marketing applications.
- Competition from larger pharmaceutical companies with greater resources.
- Funding challenges and potential need for additional capital.
- Intellectual property disputes or challenges to patent protection.
What Are the Growth Opportunities for OSTX?
- Expansion into New Therapeutic Areas: OS Therapies can leverage its OST-tADC technology to develop treatments for other solid tumors beyond osteosarcoma. The tunable nature of the drug conjugate platform allows for customization to target different cancer types, potentially opening up a broader market opportunity. The global solid tumor market is projected to reach $450 billion by 2030, offering significant growth potential for OS Therapies if it can successfully expand its pipeline.
- Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical companies or research institutions can provide OS Therapies with access to additional resources, expertise, and funding. Collaborations can accelerate the development and commercialization of its therapies, as well as expand its market reach. Strategic alliances can also validate the company's technology and attract further investment.
- Advancement of Clinical Trials: The successful completion of clinical trials for OST-HER2 and OST-tADC is crucial for OS Therapies' growth. Positive clinical data can lead to regulatory approval and commercialization, driving revenue growth and increasing shareholder value. The company's ability to efficiently manage and execute clinical trials will be a key determinant of its success.
- Securing Regulatory Approvals: Obtaining regulatory approvals from the FDA and other regulatory agencies is essential for commercializing OS Therapies' products. The company's regulatory strategy and its ability to navigate the approval process will be critical factors in its growth. Expedited review pathways, such as orphan drug designation, can accelerate the approval process and provide market exclusivity.
- Geographic Expansion: OS Therapies can expand its market reach by commercializing its products in international markets. This requires navigating different regulatory landscapes and establishing partnerships with local distributors. The global market for cancer therapeutics is growing rapidly, particularly in emerging economies, offering significant growth opportunities for OS Therapies.
What Opportunities Does OSTX Have?
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Securing regulatory approvals
- Geographic expansion
What Threats Does OSTX Face?
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Funding challenges
What Are OSTX's Competitive Advantages?
- Proprietary technology platform (OST-tADC)
- Patent protection for its therapies
- Focus on a niche market (osteosarcoma)
- Potential for orphan drug designation
What Does OSTX Do?
Founded in 2018, OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative treatments for osteosarcoma and other solid tumors. Based in Rockville, Maryland, the company is focused on addressing significant unmet needs in oncology through targeted therapies. OS Therapies' pipeline features two primary assets: OST-HER2, an off-the-shelf immunotherapy designed for osteosarcoma patients, and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology. The OST-tADC platform incorporates tunable pH-sensitive silicone linkers, offering a plug-and-play approach to drug conjugation. The company's strategic focus is on advancing these therapies through clinical trials and ultimately bringing them to market to improve patient outcomes. With a small but dedicated team, OS Therapies is committed to pioneering new treatment options in the fight against cancer, particularly in areas where existing therapies are limited or ineffective. The company's research and development efforts are centered on leveraging cutting-edge technologies to create more effective and less toxic cancer treatments.
What Products and Services Does OSTX Offer?
- Develops treatments for osteosarcoma and other solid tumors.
- Focuses on targeted therapies to address unmet needs in oncology.
- Utilizes an off-the-shelf immunotherapy approach with OST-HER2.
- Employs an antibody-drug conjugate technology with OST-tADC.
- Leverages tunable pH-sensitive silicone linkers for drug conjugation.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
How Does OSTX Make Money?
- Develops and patents novel cancer therapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties on product sales.
- Focuses on research and development to advance its pipeline.
What Industry Does OSTX Operate In?
OS Therapies Incorporated operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. OS Therapies focuses on osteosarcoma, a rare bone cancer, which allows it to target a niche market with significant unmet needs. The company competes with larger pharmaceutical companies and other biotechnology firms developing cancer treatments. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.
Who Are OSTX's Key Customers?
- Osteosarcoma patients
- Oncologists
- Hospitals and cancer centers
- Pharmaceutical companies (potential partners)
OS Therapies Incorporated (OSTX) Valuation Context
Valued at $69.92M, OSTX is classified as a micro-cap stock. Relative to its peer group, OSTX's quantitative score of 33/100 is below the peer average of 69/100.
Key Financial Metrics
Its free cash flow yield is -19.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -49.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
OS Therapies Incorporated's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.64 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project OS Therapies Incorporated revenue of about $2.7M for fiscal 2026, with EPS near $-0.70. The estimate reflects 3 contributing analysts.
OSTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- OSTX insiders seem to be positioning themselves for potential growth; recent activity suggests confidence from those who know the company best.
- The chatter in the community is definitely leaning towards optimism; people seem to believe in the long-term potential of their pipeline.
- OSTX's focus on a specific niche in the market gives them a clear path to potential leadership if things go well.
- The overall market perception of companies in the biotech space is improving, which could lift OSTX along with it.
Bear Case
- The social media buzz, while positive, might be a bit too enthusiastic; sometimes that's a signal that expectations are getting ahead of reality.
- Insider activity is interesting, but it's not always a crystal ball; could be personal reasons behind the transactions.
- OSTX operates in a highly competitive landscape; bigger players could easily overshadow their efforts.
- Recent market developments have introduced uncertainty; this could lead to a more risk-averse environment, impacting smaller companies like OSTX.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OSTX Latest News
-
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga · Jun 18, 2026
-
Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13
benzinga · May 19, 2026
-
Earnings Scheduled For May 18, 2026
benzinga · May 18, 2026
-
OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate
benzinga · May 18, 2026
OSTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OSTX.
Price Targets
Consensus target: $11.49
OSTX MoonshotScore
What does this score mean?
The MoonshotScore rates OSTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13
Earnings Scheduled For May 18, 2026
OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate
Leadership: Paul A. Romness
CEO
Paul A. Romness serves as the CEO of OS Therapies Incorporated, leading the company's efforts in developing and commercializing treatments for osteosarcoma and other solid tumors. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology drug development. He has held leadership positions in various biotech companies, overseeing research and development, clinical trials, and regulatory affairs. Romness holds advanced degrees in molecular biology and business administration, providing him with a strong foundation in both the scientific and business aspects of the industry.
Track Record: Under Paul A. Romness's leadership, OS Therapies Incorporated has advanced its pipeline of targeted therapies, including OST-HER2 and OST-tADC, through preclinical and early-stage clinical development. He has successfully secured funding to support the company's research and development efforts and has built a team of experienced scientists and clinicians. Romness has also established strategic partnerships to accelerate the development and commercialization of OS Therapies' products.
OSTX Healthcare Stock FAQ
What does OS Therapies Incorporated do?
OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for osteosarcoma and other solid tumors. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy, and OST-tADC, an antibody-drug conjugate technology. OS Therapies aims to address the unmet needs of patients with these cancers by providing targeted therapies that are more effective and less toxic than existing treatments. The company's business model involves developing and patenting novel cancer therapies, and then out-licensing or partnering with larger pharmaceutical companies for commercialization.
What do analysts say about OSTX stock?
Given OS Therapies Incorporated's market capitalization of $69.92M, analyst coverage may be limited. However, the company's focus on a niche market (osteosarcoma) and its innovative technology platform (OST-tADC) could attract attention from analysts specializing in biotechnology and oncology. Key valuation metrics to consider include the potential market size for its therapies, the stage of clinical development, and the strength of its intellectual property. Growth considerations include the successful completion of clinical trials, regulatory approvals, and strategic partnerships. The negative beta of -2.99 suggests the stock moves inversely to the market.
What are the main risks for OSTX?
OS Therapies Incorporated faces several risks inherent in the biotechnology industry. Clinical trial failures for OST-HER2 or OST-tADC could significantly impact the company's value. Regulatory delays or rejection of marketing applications could also impede its progress. Competition from larger pharmaceutical companies with greater resources poses a threat. Funding challenges and the potential need for additional capital are ongoing risks. Intellectual property disputes or challenges to patent protection could also negatively affect the company's prospects. Investors should carefully consider these risks before investing in OSTX.
What are the key factors to evaluate for OSTX?
OS Therapies Incorporated (OSTX) holds an AI score of 33/100 (low). Analysts target $11.49 (+632%). Not financial advice.
How frequently does OSTX data refresh on this page?
OSTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OSTX's recent stock price performance?
OS Therapies Incorporated (OSTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform (OST-tADC). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OSTX overvalued or undervalued right now?
Valuing OS Therapies Incorporated (OSTX) requires multiple metrics. Analysts target $11.49 (+632%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OSTX?
Before investing in OS Therapies Incorporated (OSTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is a clinical-stage biopharmaceutical company and faces significant risks associated with drug development and regulatory approval.